Catalyst
Slingshot members are tracking this event:
Pfizer Announces FDA Approval of XELJANZ XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PFE | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 24, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Xeljanz Xr, Tofacitinib Citrate, Jak Inhibitor Treatment, Rheumatoid Arthritis
